Wallis Stabilization Device

Triangle Orthopaedic Associates, P.A. is currently participating in the Wallis Stabilization device trial. We are seeking patients who have mild to moderate degenerative-disc disease and will require surgical intervention at some stage. This study will utilize either non-surgical treatment or an investigational device, consisting of a spacer and bands to align the spinal column. Patients must be willing to commit to a two year period where they will follow either the surgical or non-surgical treatment plan, whichever they are assigned.

Contact Lynn Kamm, CCRC at 919-281-1784 or email lkamm@triangleortho.com

http://www.clinicaltrials.gov/ct/show/NCT00134537?order=1

http://www.spine-health.com/research/trials/wallis/wallis.html

Cervical Spine (degenerative-disc disease)

Triangle Orthopaedic Associates, P.A. is currently participating in the Discover degenerative-disc disease trial. We are seeking patients who have mild to moderate cervical degenerative-disc disease. Subjects must be 21 to 70 years of age who present with symptomatic cervical DDD at one or two adjacent levels. Subjects will either receive a cortical or cortico-cancellous allograft spacer with a SLIM-Loc anterior cervical plate (control group) or an artificial cervical disc (investigational group). Subjects will be randomized using a 2:1 ratio (For every 1 fusion there will be 2 artificial disc assigned). Enrolled subjects will undergo post-treatment assessments prior to discharge, 2-weeks, 3, 6, 12, 24, 36, 48, and 60-months. Enrollment will run for 12 months.

Please contact Tabithia Paynter at (919) 281-1720 or email at tpaynter@triangleortho.com

Spine Stabilization vs. Fusion

Triangle Orthopaedic Associates, P.A. is currently participating in the Stabilimax NZ™ trial. We are seeking patients who have clinically symptomatic spinal stenosis at one or two contiguous vertebral levels from L1-S1. Subjects must be 21 years of age. Patients will be randomized according to a 2:1 investigative to control ratio. The two-armed study will compare Stabilimax NZ™ implanted at one or two contiguous levels to posterolateral instrumented fusion.